Emyria Limited (ASX: EMD) has opened Empax Centre, a state-of-the-art facility dedicated to the delivery and development of new treatments for mental health such as psychedelic-assisted therapies.
This purpose-built centre combines patient-centred design and cutting-edge technology and increases Emyria’s clinical service capacity to support the treatment and research of complex mental health conditions such as Post-Traumatic Stress Disorder (PTSD).
Named to reflect empathy and homage to its founding entities, Emyria and The Pax Centre, the Empax Centre is dedicated to the delivery and Real-World evaluation of new mental health treatments such as MDMA-assisted therapy for individuals with difficult-to-treat PTSD.
Emyria says the Empax Centre reflects the company’s commitment to addressing unmet needs in mental health and, at full capacity, is expected to substantially increase the company’s care delivery and research revenues as well as directly support the company’s innovation pipeline of new care models and proprietary drug therapies.
Market Potential
The Empax Centre's founding mission is to serve a significant yet underserved population — those grappling with resistant forms of PTSD, including many first responders. With an estimated one million Australians living with PTSD, and a substantial portion not responding to standard treatments, the Empax Centre is uniquely positioned to address this gap by supporting new treatment research such as the recently announced study with charity Reach Wellness, to evaluate MDMA-AT for first responders with PTSD . The Empax Centre will be the trial location for the Reach Wellness study.
Innovation and Excellence in Care
Led by pioneers in the field, including two of Australia’s first authorised prescribers of MDMA-assisted therapy, the Empax Centre has a supporting team of over 14 clinicians specially trained in psychedelic-assisted therapy. The facility is therefore designed to support the unique requirements of these treatments including dedicated spaces to ensure patient comfort and safety over extended sessions, complemented by advanced audio-visual (AV) monitoring and an AI-generated music system for an unparalleled therapeutic experience.
The Centre is expected to become a centre of excellence for care delivery and research and development and a core focus of the Empax Centre is to capture robust clinical evidence while providing unparalleled patient care. This data-driven approach supports Emyria's long-term innovation agenda which involves actively developing new and improved care models as well as novel drug treatments inspired by MDMA.
